The University of Southampton
University of Southampton Institutional Repository

Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomised controlled trial

Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomised controlled trial
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomised controlled trial
Background: evidence linking prenatal maternal vitamin D supplementation with the offspring’s risk of atopic eczema is inconsistent, with most data coming from observational studies.

Objectives: to examine the influence of maternal cholecalciferol supplementation during pregnancy on the risk of atopic eczema in the offspring at ages 12, 24 and 48 months.

Methods: within the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS) double-blind, randomized placebo-controlled trial, we examined the relationship of maternal vitamin D supplementation during pregnancy with offspring atopic eczema at ages 12, 24 and 48 months. In MAVIDOS, pregnant women were allocated to either cholecalciferol 1000 IU per day or matched placebo, taken from around 14 weeks’ gestation until delivery, with the primary outcome of neonatal whole-body bone mineral content. The prevalence of atopic eczema in the offspring was ascertained at ages 12 (n = 635), 24 (n = 610) and 48 (n = 449) months, based on the UK Working Party criteria for the definition of atopic dermatitis. The trial was registered with ISRCTN (82927713) and EudraCT (2007-001716-23).

Results: the characteristics of mothers and offspring were similar between the intervention and placebo groups, apart from longer breastfeeding duration in the intervention group. Adjusting for breastfeeding duration, offspring of mothers who received cholecalciferol 1000 IU daily had a lower odds ratio (OR) of atopic eczema at age 12 months [OR 0·55, 95% confidence interval (CI) 0·32–0·97, P = 0·04]; this effect weakened and was not statistically significant at ages 24 months (OR 0·76, 95% CI 0·47–1·23) or 48 months (OR 0·75, 95% CI 0·37–1·52). The statistical interaction of intervention and breastfeeding duration in relation to eczema at age 12 months was not significant (P = 0·41), but stratification showed reduced infantile eczema risk in the intervention group for infants breastfed for ≥ 1 month (OR 0·48, 95% CI 0·24–0·94, P = 0·03) but not in those breastfed for < 1 month (OR 0·80, 95% CI 0·29–2·17, P = 0·66).

Conclusions: our data provide the first randomized controlled trial evidence of a protective effect of antenatal cholecalciferol supplementation on the risk of infantile atopic eczema, with the effect potentially being via increased breast milk cholecalciferol levels. The findings support a developmental influence on atopic eczema, and point to a potentially modifiable perinatal influence on atopic eczema.
0007-0963
659-666
El-Heis, Sarah
6d7d2e03-3d63-4510-8b7e-fcbe4653db13
D'angelo, Stefania
13375ecd-1117-4b6e-99c0-32239f52eed6
Curtis, Elizabeth
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Healy, Eugene
Moon, Rebecca
954fb3ed-9934-4649-886d-f65944985a6b
Crozier, Sarah
9c3595ce-45b0-44fa-8c4c-4c555e628a03
Inskip, Hazel
5fb4470a-9379-49b2-a533-9da8e61058b7
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Godfrey, Keith
0931701e-fe2c-44b5-8f0d-ec5c7477a6fd
MAVIDOS Trial Group
El-Heis, Sarah
6d7d2e03-3d63-4510-8b7e-fcbe4653db13
D'angelo, Stefania
13375ecd-1117-4b6e-99c0-32239f52eed6
Curtis, Elizabeth
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Healy, Eugene
Moon, Rebecca
954fb3ed-9934-4649-886d-f65944985a6b
Crozier, Sarah
9c3595ce-45b0-44fa-8c4c-4c555e628a03
Inskip, Hazel
5fb4470a-9379-49b2-a533-9da8e61058b7
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Godfrey, Keith
0931701e-fe2c-44b5-8f0d-ec5c7477a6fd

El-Heis, Sarah, D'angelo, Stefania, Curtis, Elizabeth, Healy, Eugene, Moon, Rebecca, Crozier, Sarah, Inskip, Hazel, Cooper, Cyrus, Harvey, Nicholas and Godfrey, Keith , MAVIDOS Trial Group (2022) Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomised controlled trial. British Journal of Dermatology, 187 (5), 659-666. (doi:10.1111/bjd.21721).

Record type: Article

Abstract

Background: evidence linking prenatal maternal vitamin D supplementation with the offspring’s risk of atopic eczema is inconsistent, with most data coming from observational studies.

Objectives: to examine the influence of maternal cholecalciferol supplementation during pregnancy on the risk of atopic eczema in the offspring at ages 12, 24 and 48 months.

Methods: within the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS) double-blind, randomized placebo-controlled trial, we examined the relationship of maternal vitamin D supplementation during pregnancy with offspring atopic eczema at ages 12, 24 and 48 months. In MAVIDOS, pregnant women were allocated to either cholecalciferol 1000 IU per day or matched placebo, taken from around 14 weeks’ gestation until delivery, with the primary outcome of neonatal whole-body bone mineral content. The prevalence of atopic eczema in the offspring was ascertained at ages 12 (n = 635), 24 (n = 610) and 48 (n = 449) months, based on the UK Working Party criteria for the definition of atopic dermatitis. The trial was registered with ISRCTN (82927713) and EudraCT (2007-001716-23).

Results: the characteristics of mothers and offspring were similar between the intervention and placebo groups, apart from longer breastfeeding duration in the intervention group. Adjusting for breastfeeding duration, offspring of mothers who received cholecalciferol 1000 IU daily had a lower odds ratio (OR) of atopic eczema at age 12 months [OR 0·55, 95% confidence interval (CI) 0·32–0·97, P = 0·04]; this effect weakened and was not statistically significant at ages 24 months (OR 0·76, 95% CI 0·47–1·23) or 48 months (OR 0·75, 95% CI 0·37–1·52). The statistical interaction of intervention and breastfeeding duration in relation to eczema at age 12 months was not significant (P = 0·41), but stratification showed reduced infantile eczema risk in the intervention group for infants breastfed for ≥ 1 month (OR 0·48, 95% CI 0·24–0·94, P = 0·03) but not in those breastfed for < 1 month (OR 0·80, 95% CI 0·29–2·17, P = 0·66).

Conclusions: our data provide the first randomized controlled trial evidence of a protective effect of antenatal cholecalciferol supplementation on the risk of infantile atopic eczema, with the effect potentially being via increased breast milk cholecalciferol levels. The findings support a developmental influence on atopic eczema, and point to a potentially modifiable perinatal influence on atopic eczema.

Text
Br J Dermatol - 2022 - El‐Heis - Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the - Version of Record
Available under License Creative Commons Attribution.
Download (763kB)

More information

e-pub ahead of print date: 28 June 2022

Identifiers

Local EPrints ID: 468270
URI: http://eprints.soton.ac.uk/id/eprint/468270
ISSN: 0007-0963
PURE UUID: 5c698b44-aa52-4079-bd90-1d10f16d89b6
ORCID for Stefania D'angelo: ORCID iD orcid.org/0000-0002-7267-1837
ORCID for Elizabeth Curtis: ORCID iD orcid.org/0000-0002-5147-0550
ORCID for Sarah Crozier: ORCID iD orcid.org/0000-0002-9524-1127
ORCID for Hazel Inskip: ORCID iD orcid.org/0000-0001-8897-1749
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709
ORCID for Nicholas Harvey: ORCID iD orcid.org/0000-0002-8194-2512
ORCID for Keith Godfrey: ORCID iD orcid.org/0000-0002-4643-0618

Catalogue record

Date deposited: 09 Aug 2022 16:38
Last modified: 22 Nov 2022 02:46

Export record

Altmetrics

Contributors

Author: Sarah El-Heis
Author: Stefania D'angelo ORCID iD
Author: Eugene Healy
Author: Rebecca Moon
Author: Sarah Crozier ORCID iD
Author: Hazel Inskip ORCID iD
Author: Cyrus Cooper ORCID iD
Author: Nicholas Harvey ORCID iD
Author: Keith Godfrey ORCID iD
Corporate Author: MAVIDOS Trial Group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×